Long-term Investigation of Resveratrol in Obesity (LIRMOI)
Status
Conditions
Treatments
Details and patient eligibility
About
The aim of this study is to investigate potential metabolic effects of resveratrol in men with metabolic syndrome(otherwise healthy).
The investigators hypothesize that resveratrol has an anti-inflammatory effect, and will increase insulin sensitivity, change the fat- and sugar-metabolism, and down-regulate bone-turnover.
Full description
The study will be done in a collaboration between two PhD students, who focus on effects in adipose- and muscle- tissue, and bone tissue respectively.
The investigators will look at changes in
- inflammation-markers
- biochemical markers of fat- and sugar-metabolism
- gene-expression in fat- and muscle-tissue
- body composition (DXA (whole body) and MR spectroscopy)
- biochemical markers of bone-metabolism
- Bone Mineral Density (DXA scans)
- bone structure (QCT)
- gene-expression and cytokines in bone marrow
Some of the volunteers will have their insulin sensitivity measured.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Male
- 30-60 years old
- Metabolic Syndrome
- Written informed consent
Exclusion criteria
- Diabetes, thyroid or parathyroid disease, hypogonadism
- Treatment-requiring osteoporosis
- Heart, liver or kidney disease
- Present or previous malignancy
- MR contraindication
- Alcohol dependency
- Weight > 130 kilograms
Trial design
Primary purpose
Allocation
Interventional model
Masking
76 participants in 3 patient groups, including a placebo group
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal